Developing biologics is a BIG industry. Current trends show
that large pharmaceutical companies are investing in mAbs,
ADCs, and other biologically-derived treatments, as they offer
a good chance for ultimate success in the clinic. And, in light of
the recent COVID-19 pandemic, mAb-based treatments have
been able to move to market faster. At present, North America
dominates the biologics market, but the market share of
biologics research is growing in the EU and Asia as well.
Let's talk about what biologics are, how they're produced, and
how to increase the chance of successfully developing biologics
for patients.
The growing
interest in
biologics
1
6
